ArticleKidney international reports2022
A Novel Scoring System Based on Oxford Classification Indicating Steroid Therapy Use for IgA Nephropathy.
Article in Kidney international reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Burden of corticosteroid therapy in patients with immunoglobulin A nephropathy (IgAN): a systematic literature review.BMC nephrology · 2025Pooled it
- IgA nephropathy management: what does the future hold?Kidney international supplements · 2026Review
- Guiding immunotherapy based on the oxford classification activity score in IgA nephropathy.Frontiers in endocrinology · 2026Article
- New Insights on IgA Nephropathy from the Perspective of Active Lesions and Systemic Inflammatory Responses.ImmunoTargets and therapy · 2026Review
- Prognostic value of the MEST-C score in long-term outcomes of immunoglobulin A nephropathy patients: Insights from a developing country.World journal of nephrology · 2025Article
- Bridging pediatric and adult IgAN: challenges in applying proteinuria-driven recommendations in the new IPNA guidelines.Pediatric nephrology (Berlin, Germany) · 2025Article
- An Expert Opinion on Current and Future Treatment Approaches in IgA Nephropathy.Advances in therapy · 2025Article
- Urine complement-related proteins in IgA nephropathy and IgA vasculitis nephritis, possible biomarkers of disease activity.Clinical kidney journal · 2025Article
- Prognostic Utility of the MEST-C Score Combined With Clinical Parameters in Hispanic Patients With IgA Nephropathy.International journal of nephrology · 2025Article
- MEST C Score and Treatment Response in IgA Nephropathy in a Tertiary Care Hospital: A Descriptive Cross-sectional Study.JNMA; journal of the Nepal Medical Association · 2024Article
- Points of view in nephrology: personalized management of IgA nephropathy, beyond KDIGO.Journal of nephrology · 2024Review
- IgA nephropathy in children with minimal proteinuria: to biopsy or not to biopsy?Pediatric nephrology (Berlin, Germany) · 2024Article
- Systematic Review of the Link Between Oxford MEST-C Classification and Complement Activation in IgA Nephropathy.Kidney international reports · 2024Article
- Use of corticosteroids in Norwegian patients with immunoglobulin a nephropathy progressing to end-stage kidney disease: a retrospective cohort study.BMC nephrology · 2024Article
- A lack of KDIGO guidelines for adolescents and young adults with IgA nephropathy.Pediatric nephrology (Berlin, Germany) · 2024Review
- The predictive value and response to immunosuppressive therapy of IgA nephropathy patients with crescents in a large retrospective Chinese cohort.Clinical kidney journal · 2023Article
- Evaluating Progression Risk in Patients With Immunoglobulin A Nephropathy.Kidney international reports · 2023Review
- Systemic and targeted steroids for the treatment of IgA nephropathy.Clinical kidney journal · 2023Review
- Long-term follow-up of IgA nephropathy: clinicopathological features and predictors of outcomes.Clinical kidney journal · 2023Article
- IgA nephropathy.Nature reviews. Disease primers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe usefulness of the Oxford classification (MEST-C score) for deciding the management approach for IgA nephropathy (IgAN) remains unclear.
methodsEffects of steroid therapy on the long-term prognosis for all 858 patients with IgAN and patients classified according to each MEST-C score were evaluated using Kaplan-Meier and Cox regression analyses. Steroid responder score (SRS) and steroid nonresponder score (SNRS) were determined using individual pathology scores when steroids were found to be independently associated, or not, with clinical benefits. In addition, the effects of steroid therapy according to the total SRS/SNRS were analyzed.
resultsSteroid therapy improved the 20-year renal survival rates of patients with IgAN after matching (steroids[+] vs. steroids[-]; estimated glomerular filtration rate [eGFR] [ml/min per 1.73 m
conclusionPatients with M1, E1, S1, and C1+2 scores responded to steroid therapy; however, those with T1+2 scores did not. Although a high SRS was a useful indicator for steroid therapy, SNRS indicated resistance to steroid therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.